Jun 10 2011
Biota Holdings Limited (ASX:BTA) advises that its wholly owned subsidiary, Biota Scientific Management Pty Ltd, has been awarded a grant to fund the preclinical development of a lead candidate for the treatment of Clostridium difficile (C. difficile).
The first years payment is US$830,287 of a 5 year grant totalling US$2.9m. Future payments to Biota are subject to satisfactory project progress and the availability of funding.
The award (Number ROI A1094456) is from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) of the U.S. Department of Health and Human Services (HHS).
The C. difficile program was part of the assets acquired from Prolysis in November 2009.